NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

Law & Health Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Law & Health Weekly

Learn More

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



Avant Immunotherapeutics



Avant receives $4M milestone payment from GlaxoSmithKline for rotavirus vaccine



April 8th, 2006

Avant Immunotherapeutics (AVAN) has received a $4 million milestone payment from GlaxoSmithKline (GSK).

This payment marks the approval from the European Commission for Rotarix in the European Union (E.U.). Rotarix will be the first rotavirus vaccine available to children in Europe for the prevention of gastroenteritis caused by rotavirus.

"We are very gratified to receive this milestone payment, which marks a key event in the worldwide commercialization of Rotarix," said Una S. Ryan, PhD, Avant president and CEO. "This approval also leads to a substantial payment of $40 million to Avant through its transaction with Paul Royalty Fund [PRF]."

...


Source: Law & Health Weekly (2006-04-08)

NewsRx Passes
Advertisement
More Articles

------------------------
Security by Verisign PR Login